Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients

H. Hermesh; D. Aizenberg; A. Weizman; M. Lapidot; C. Mayor; H. Munitz

doi:10.1192/bjp.161.2.254

Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients

H. Hermesh^*, D. Aizenberg, A. Weizman, M. Lapidot, C. Mayor, H. Munitz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly overrepresented in the NMS group.

Original language	English
Pages (from-to)	254-257
Number of pages	4
Journal	British Journal of Psychiatry
Volume	161
Issue number	AUG.
DOIs	https://doi.org/10.1192/bjp.161.2.254
State	Published - 1992
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1192/bjp.161.2.254

Cite this

@article{107c2ed80d894704a139bb4ebd32a290,

title = "Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients",

abstract = "The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly overrepresented in the NMS group.",

author = "H. Hermesh and D. Aizenberg and A. Weizman and M. Lapidot and C. Mayor and H. Munitz",

year = "1992",

doi = "10.1192/bjp.161.2.254",

language = "אנגלית",

volume = "161",

pages = "254--257",

journal = "British Journal of Psychiatry",

issn = "0007-1250",

publisher = "Royal College of Psychiatrists",

number = "AUG.",

}

TY - JOUR

T1 - Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients

AU - Hermesh, H.

AU - Aizenberg, D.

AU - Weizman, A.

AU - Lapidot, M.

AU - Mayor, C.

AU - Munitz, H.

PY - 1992

Y1 - 1992

N2 - The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly overrepresented in the NMS group.

AB - The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly overrepresented in the NMS group.

UR - http://www.scopus.com/inward/record.url?scp=0026712110&partnerID=8YFLogxK

U2 - 10.1192/bjp.161.2.254

DO - 10.1192/bjp.161.2.254

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0026712110

SN - 0007-1250

VL - 161

SP - 254

EP - 257

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

IS - AUG.

ER -

Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this